

Status of NICE TAs & HSTs on Gloucestershire Joint Formulary Published from 2022

No.	NICE TA / HST (click to open link)	Compliant (Y/N)	Location on Formulary
TA757	Cabotegravir with rilpivirine for treating HIV-1	Y	No Chapter 5
TA758	Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy	Y	Chapter 4
TA759	Fostamatinib for treating refractory chronic immune thrombocytopenia	Negative recommendation	
TA760	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer	Y	Chapter 8 incomplete
TA761	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	Y	Chapter 8 incomplete
TA762	Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)	Terminated appraisal	
TA763	Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable	Y	Chapter 8 incomplete
TA764	Fremanezumab for preventing migraine	Y	Chapter 4
TA765	Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	Y	Chapter 8 incomplete
TA766	Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma	Y	Chapter 8 incomplete
TA767	Ponesimod for treating relapsing–remitting multiple sclerosis	Y	Chapter 8 incomplete
TA768	Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs	Y	Chapter 10
TA769	Palforzia for treating peanut allergy in children and young people	Y	Chapter 3
TA770	Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer	Y	Chapter 8 incomplete
TA771	Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)	Terminated appraisal	
TA772	Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies	Y	Chapter 8 incomplete
TA773	Empagliflozin for treating chronic heart failure with reduced ejection fraction	Y	Chapter 2
TA774	Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)	Terminated appraisal	
TA775	Dapagliflozin for treating chronic kidney disease	Y	Chapter 6
TA776	Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea	Negative recommendation	
TA777	Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea	Negative recommendation	
TA778	Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria	Y	Chapter 9
TA779	Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	Y	Chapter 8 incomplete
TA780	Nivolumab with ipilimumab for untreated advanced renal cell carcinoma	Y	Chapter 8 incomplete
TA781	Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	Y	Chapter 8 incomplete
TA782	Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)	Terminated appraisal	
HST17	Odevixibat for treating progressive familial intrahepatic cholestasis	Y	Chapter 1
HST18	Atidarsagene autotemcel for treating metachromatic leukodystrophy	Y	Specialist Centres Only
TA783	Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	Y	Chapter 8 incomplete
TA784	Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer	Y	Chapter 8 incomplete
HST19	Elosulfase alfa for treating mucopolysaccharidosis type 4A	Y	Chapter 9
TA785	Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)	Terminated appraisal	
TA786	Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies	Y	Chapter 8 incomplete
TA787	Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	Y	Chapter 8 incomplete
TA788	Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy	Y	Chapter 8 incomplete
TA789	Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations	Y	Chapter 8 incomplete

TA790	TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)	Terminated appraisal	
TA791	Romosozumab for treating severe osteoporosis	Y	Chapter 6
TA792	Filgotinib for treating moderately to severely active ulcerative colitis	Y	Chapter 1
TA793	Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)		
TA794	Diroximel fumarate for treating relapsing–remitting multiple sclerosis	Y	Chapter 8 incomplete
TA795	Ibrutinib for treating Waldenstrom's macroglobulinaemia	Negative recommendation	
TA796	Venetoclax for treating chronic lymphocytic leukaemia	Y	Chapter 8 incomplete
TA797	Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)	Negative recommendation	
TA798	Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation	Y	Chapter 8 incomplete
TA799	Faricimab for treating diabetic macular oedema	Y	Chapter 11
TA800	Faricimab for treating wet age-related macular degeneration	Y	Chapter 11
TA801	Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer	Y	Chapter 8 incomplete
TA802	Cemiplimab for treating advanced cutaneous squamous cell carcinoma	Y	Chapter 8 incomplete
TA803	Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs	Y	Chapter 10
TA804	Teduglutide for treating short bowel syndrome	Y	Chapter 1
TA805	Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides	Y	Chapter 2
TA806	Belimumab for treating lupus nephritis (terminated appraisal)	Terminated appraisal	
TA807	Roxadustat for treating symptomatic anaemia in chronic kidney disease	Y	Chapter 9
TA808	Fenfluramine for treating seizures associated with Dravet syndrome	Y	Chapter 4
TA809	Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	Y	Chapter 8 incomplete
TA810	Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence	Y	Chapter 8 incomplete
TA811	Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)	Terminated appraisal	
TA812	Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer	Negative recommendation	
TA813	Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors	Y	Chapter 8 incomplete
TA814	Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis	Y	Chapter 13
TA815	Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs	Y	Chapter 10
TA816	Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer	Y	Chapter 8 incomplete
TA817	Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence	Y	Chapter 8 incomplete
TA818	Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma	Y	Chapter 8 incomplete
TA819	Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies	Y	Chapter 8 incomplete
TA820	Brolucizumab for treating diabetic macular oedema	Y	Chapter 11
TA821	Avalglucosidase alfa for treating Pompe disease	Y	Chapter 9
HST19	Elosulfase alfa for treating mucopolysaccharidosis type 4A	Y	Chapter 9
HST20	Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over	Y	Chapter 8 incomplete
HST21	Setmelanotide for treating obesity caused by LEPR or POMC deficiency	Y	Chapter 6
TA822	Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)	Terminated appraisal	
TA823	Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer	Y	Chapter 8 incomplete
TA824	Dexamethasone intravitreal implant for treating diabetic macular oedema	Y	Chapter 11
TA825	Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis	Y	Chapter 10
TA826	Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)	Terminated appraisal	

TA827	Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy	Y	Chapter 8 incomplete
TA828	Ozanimod for treating moderately to severely active ulcerative colitis	Y	Chapter 1
TA829	Upadacitinib for treating active ankylosing spondylitis	Y	Chapter 10
TA830	Pembrolizumab for adjuvant treatment of renal cell carcinoma	Y	Chapter 8 incomplete
TA831	Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	Negative recommendation	
TA832	Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids	Y	Chapter 6
TA833	Zanubrutinib for treating Waldenstrom's macroglobulinaemia	Y	Chapter 8 incomplete
TA834	SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)		
TA835	Fostamatinib for treating refractory chronic immune thrombocytopenia	Y	Chapter 9
TA836	Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	Y	Chapter 8 incomplete
TA837	Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma	Y	Chapter 8 incomplete
TA838	Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)	Terminated appraisal	
TA839	Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)	Terminated appraisal	
TA840	Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)	Terminated appraisal	
TA841	Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	Terminated appraisal	
TA842	Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)	Terminated appraisal	
TA843	Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)	Terminated appraisal	
TA844	Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)	Terminated appraisal	
TA845	Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)	Terminated appraisal	
TA846	Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)	Terminated appraisal	
TA847	Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)	Terminated appraisal	
TA848	Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)	Terminated appraisal	
TA849	Cabozantinib for previously treated advanced hepatocellular carcinoma	Y	Chapter 8 incomplete
TA850	Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	Negative recommendation	
TA851	Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer	Y	Chapter 8 incomplete
TA852	Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments	Y	Chapter 8 incomplete
TA853	Avatrombopag for treating primary chronic immune thrombocytopenia	Y	Chapter 9
TA854	Esketamine nasal spray for treatment-resistant depression	Negative recommendation	
TA855	Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	Y	Chapter 8 incomplete
TA856	Upadacitinib for treating moderately to severely active ulcerative colitis	Y	Chapter 1
TA857	Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	Y	Chapter 8 incomplete
TA858	Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma	Y	Chapter 8 incomplete
TA859	Angiotensin II for treating vasopressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)	Terminated appraisal	
TA860	Maribavir for treating refractory cytomegalovirus infection after transplant	Y	No Chapter 5
TA861	Upadacitinib for treating active non-radiographic axial spondyloarthritis	Y	Chapter 10
TA862	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	Y	Chapter 8 incomplete
TA863	Somatrogon for treating growth disturbance in children and young people aged 3 years and over	Y	Chapter 6

TA864	Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	Y	Chapter 8 incomplete
TA865	Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	Y	Chapter 8 incomplete
TA866	Regorafenib for previously treated metastatic colorectal cancer	Y	Chapter 8 incomplete
TA867	Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)	Terminated appraisal	
TA868	Vutrisiran for treating hereditary transthyretin-related amyloidosis	Y	Chapter 4
TA869	Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)	Terminated appraisal	
TA870	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	Y	Chapter 8 incomplete
HST22	Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene	Y	Chapter 10
TA871	Eptinezumab for preventing migraine	Y	Chapter 4
TA872	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	Y	Chapter 8 incomplete
TA873	Cannabidiol for treating seizures caused by tuberous sclerosis complex	Y	Chapter 4
TA874	Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma	Y	Chapter 8 incomplete
HST23	Asfotase alfa for treating paediatric-onset hypophosphatasia	Y	Chapter 9
TA875	Semaglutide for managing overweight and obesity	Y	Chapter 4
TA876	Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer	Y	Chapter 8 incomplete
TA877	Finerenone for treating chronic kidney disease in type 2 diabetes	Y	Chapter 1
TA878	Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19	Y	No Chapter 5
TA879	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)	Terminated appraisal	
HST24	Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy	Y	Chapter 10
HST25	Lumasiran for treating primary hyperoxaluria type 1	Y	Chapter 9
HST26	Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency	Y	Chapter 9
TA880	Tezepelumab for treating severe asthma	Y	Chapter 3
TA881	Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments	Negative recommendation	
TA882	Voclosporin with mycophenolate mofetil for treating lupus nephritis	Y	Chapter 8 incomplete
TA883	Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma	Negative recommendation	
TA884	Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)	Terminated appraisal	
TA885	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	Y	Chapter 8 incomplete
TA886	Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	Y	Chapter 8 incomplete
TA887	Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	Y	Chapter 8 incomplete
TA888	Risankizumab for previously treated moderately to severely active Crohn's disease	Y	Chapter 1
TA889	Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)	Terminated appraisal	
TA890	Difelikefalin for treating pruritus in people having haemodialysis	Y	Chapter 4
TA891	Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia	Y	Chapter 8 incomplete
TA892	Mosunetuzumab for treating relapsed or refractory follicular lymphoma	Negative recommendation	
TA893	Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	Y	Chapter 8 incomplete
TA894	Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma	Negative recommendation	
TA895	Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	Y	Chapter 8 incomplete
TA896	Bulevirtide for treating chronic hepatitis D	Y	No Chapter 5
TA897	Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	Y	Chapter 8 incomplete

TA898	Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer	Y	Chapter 8 incomplete
TA899	Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)	Terminated appraisal	
TA900	Tixagevimab plus cilgavimab for preventing COVID-19	Negative recommendation	
TA901	Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)	Terminated appraisal	
TA902	Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	Y	Chapter 2
TA903	Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer	Y	Chapter 8 incomplete
TA904	Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer	Y	Chapter 8 incomplete
TA905	Upadacitinib for previously treated moderately to severely active Crohn's disease	Y	Chapter 1
TA906	Rimegepant for preventing migraine	Y	Chapter 4
TA907	Deucravacitinib for treating moderate to severe plaque psoriasis	Y	Chapter 13
TA908	Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy	Y	Chapter 8 incomplete
TA909	Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer	Negative recommendation	
TA910	Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)	Terminated appraisal	
TA911	Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer	Y	Chapter 8 incomplete
HST27	Afamelanotide for treating erythropoietic protoporphyria	Negative recommendation	
TA912	Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease	Y	Chapter 9
TA913	Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy	Y	Chapter 2
TA914	Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency	Y	Chapter 8 incomplete
HST28	Birch bark extract for treating epidermolysis bullosa	Y	Chapter 13
TA915	Pegunigalsidase alfa for treating Fabry disease	Y	Chapter 9
TA916	Bimekizumab for treating active psoriatic arthritis	Y	Chapter 10
TA917	Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	Y	Chapter 8 incomplete
TA918	Bimekizumab for treating axial spondyloarthritis	Y	Chapter 10
TA919	Rimegepant for treating migraine	Y	Chapter 4
TA920	Tofacitinib for treating active ankylosing spondylitis	Y	Chapter 10
TA921	Ruxolitinib for treating polycythaemia vera	Y	Chapter 8 incomplete
TA922	Daridorexant for treating long-term insomnia	Y	Chapter 4
TA923	Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)	Terminated appraisal	
TA924	Tirzepatide for treating type 2 diabetes	Y	Chapter 6
TA925	Mirikizumab for treating moderately to severely active ulcerative colitis	Y	Chapter 1
TA926	Baricitinib for treating severe alopecia areata	Negative recommendation	
TA927	Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	Y	Chapter 8 incomplete
TA928	Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine	Negative recommendation	
TA929	Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	Y	Chapter 2
TA930	Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments	Negative recommendation	
TA931	Zanubrutinib for treating chronic lymphocytic leukaemia	Y	Chapter 8 incomplete
TA932	Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)	Terminated appraisal	
TA933	Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)	Terminated appraisal	
TA934	Foslevodopa–foscarnidopa for treating advanced Parkinson's with motor symptoms	Y	Chapter 4
TA935	Secukinumab for treating moderate to severe hidradenitis suppurativa	Y	Chapter 13

TA936	Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)	Terminated appraisal	
TA937	Targeted-release budesonide for treating primary IgA nephropathy	Y	Chapter 8
TA938	Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)	Terminated appraisal	
TA939	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	Y	Chapter 8 incomplete
TA940	Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)	Terminated appraisal	
TA941	Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)	Terminated appraisal	
TA942	Empagliflozin for treating chronic kidney disease	Y	Chapter 6
TA943	Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes	Not drug related	
HST29	Velmanase alfa for treating alpha-mannosidosis	Y	Chapter 9
TA944	Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer	Y	Chapter 8 incomplete
TA945	Tresulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)	Terminated appraisal	
TA946	Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer	Y	Chapter 8 incomplete
TA947	Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments	Y	Chapter 8 incomplete
TA948	Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments	Y	Chapter 8 incomplete
HST30	Sebelipase alfa for treating Wolman disease	Y	Chapter 9
TA949	Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over	Y	Chapter 8 incomplete
TA950	Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over	Y	Chapter 8 incomplete
TA951	Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer	Y	Chapter 8 incomplete
TA952	Talzoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations	Y	Chapter 8 incomplete
TA953	Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema	Y	Chapter 11
TA954	Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	Y	Chapter 8 incomplete
TA955	Dupilumab for treating moderate to severe prurigo nodularis	Negative recommendation	
TA956	Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over	Y	Chapter 1
TA957	Momelotinib for treating myelofibrosis-related splenomegaly or symptoms	Y	Chapter 8 incomplete
TA958	Ritlecitinib for treating severe alopecia areata in people 12 years and over	Y	Chapter 13
TA959	Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis	Y	Chapter 8 incomplete
TA960	Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)	Terminated appraisal	
TA961	Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)	Terminated appraisal	
TA962	Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	Y	Chapter 8 incomplete
TA963	Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	Y	Chapter 8 incomplete
TA964	Cabozantinib with nivolumab for untreated advanced renal cell carcinoma	Y	Chapter 8 incomplete
TA965	Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)	Terminated appraisal	
TA966	Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)	Terminated appraisal	
TA967	Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over	Y	Chapter 8 incomplete
TA968	Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	Terminated appraisal	
TA969	Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)	Terminated appraisal	

TA970	Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments	Y	Chapter 8 incomplete
TA971	Remdesivir and tixagevimab plus cilgavimab for treating COVID-19	Y	No Chapter 5
TA972	Sunitinib for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)	Terminated appraisal	
HST31	Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome	Y	Chapter 4
TA973	Atogepant for preventing migraine	Y	Chapter 4
TA974	Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments	Y	Chapter 8 incomplete
TA975	Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under	Y	Chapter 8 incomplete
TA976	Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)	Terminated appraisal	
TA977	Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	Y	Chapter 8 incomplete
TA978	Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)	Terminated appraisal	
TA979	Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation	Y	Chapter 8 incomplete
TA980	Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)	Terminated appraisal	
TA981	Voxelotor for treating haemolytic anaemia caused by sickle cell disease	Y	Chapter 9
TA982	Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)	Terminated appraisal	
TA983	Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma	Y	Chapter 8 incomplete
TA984	Tafamidis for treating transthyretin amyloidosis with cardiomyopathy	Y	Chapter 2
TA985	Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma	Y	Chapter 8 incomplete
TA986	Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over	Y	Chapter 13
TA987	Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)	Terminated appraisal	
TA988	Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis	Y	Chapter 3
TA989	Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B	Y	Chapter 9
TA990	Tenecteplase for treating acute ischaemic stroke	Y	Chapter 2
TA991	Abaloparatide for treating osteoporosis after menopause	Y	Chapter 6
TA992	Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy	Negative recommendation	
TA993	Burosumab for treating X-linked hypophosphataemia in adults	Y	Chapter 6
TA994	Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)	Terminated appraisal	
TA995	Relugolix for treating hormone-sensitive prostate cancer	Y	Chapter 8
TA996	Linzagolix for treating moderate to severe symptoms of uterine fibroids	Y	Chapter 6
TA997	Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma	Y	Chapter 8 incomplete
TA998	Risankizumab for treating moderately to severely active ulcerative colitis	Y	Chapter 1
TA999	Vibegron for treating symptoms of overactive bladder syndrome	Y	Chapter 7
TA1000	Iptacopan for treating paroxysmal nocturnal haemoglobinuria	Y	Chapter 9
TA1001	Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment	Y	Chapter 8 incomplete
TA1002	Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over	Y	Chapter 2
TA1003	Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over	Y	Chapter 9
TA1004	Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion	Y	Chapter 11

TA1005	Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement	Y	Chapter 8 incomplete
TA1006	Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)	Terminated appraisal	
TA1007	Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	Y	Chapter 8 incomplete
TA1008	Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments	Y	Chapter 8 incomplete
TA1009	Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension	Y	Chapter 11
TA1010	Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria	Y	Chapter 9
TA1011	Belzutifan for treating tumours associated with von Hippel-Lindau disease	Y	Chapter 8 incomplete
TA1012	Avapritinib for treating advanced systemic mastocytosis	Y	Chapter 8 incomplete
TA1013	Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia	Y	Chapter 8 incomplete
TA1014	Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer	Y	Chapter 8 incomplete
TA1015	Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments	Y	Chapter 8 incomplete
TA1016	Elafibranor for previously treated primary biliary cholangitis	Y	Chapter 1
TA1017	Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer	Y	Chapter 8 incomplete
TA1018	Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis	Y	Chapter 8 incomplete
TA1019	Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over	Y	Chapter 9
TA1020	Eplontersen for treating hereditary transthyretin-related amyloidosis	Y	Chapter 4
TA1021	Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer	Y	Chapter 8 incomplete
TA1022	Bevacizumab gamma for treating wet age-related macular degeneration	Y	Chapter 11
TA1023	Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments	Y	Chapter 8 incomplete
TA1024	Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)	Terminated appraisal	
TA1025	Ublituximab for treating relapsing multiple sclerosis	Y	Chapter 8
TA1026	Tirzepatide for managing overweight and obesity	Y	Chapter 4
TA1027	Tebentafusp for treating advanced uveal melanoma	Y	Chapter 8 incomplete
TA1028	Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)	Terminated appraisal	
TA1029	Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)	Terminated appraisal	
TA1030	Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer	Y	Chapter 8 incomplete
TA1031	Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over	Y	Chapter 6
TA1032	Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)	Terminated appraisal	
TA1033	Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over	Negative recommendation	
TA1034	Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours	Y	Chapter 8 incomplete
TA1035	Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease	Y	Chapter 9
TA1036	Elaeostrol for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment	Y	Chapter 8 incomplete
TA1037	Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer	Y	Chapter 8 incomplete
TA1038	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over	Y	Chapter 8 incomplete
TA1039	Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over	Y	Chapter 8 incomplete
TA1040	Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy	Y	Chapter 8 incomplete
TA1041	Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer	Y	Chapter 8 incomplete

TA1042	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer	Y	Chapter 8 incomplete
TA1043	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	Y	Chapter 8 incomplete
TA1044	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over	Y	Chapter 9
TA1045	12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites	Y	Chapter 3
TA1046	Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma	Negative recommendation	
TA1047	Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)	Terminated appraisal	
TA1048	Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable	Y	Chapter 8 incomplete
TA1049	Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia	Y	Chapter 8 incomplete
TA1050	Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over	Y	Chapter 4
TA1051	Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over	Y	Chapter 2
TA1052	Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)	Terminated appraisal	
HST32	Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B	Negative recommendation	
TA1053	Cladribine for treating active relapsing forms of multiple sclerosis	Y	Chapter 8
TA1054	Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over	Y	Chapter 8 incomplete
TA1055	Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	Y	Chapter 8 incomplete
TA1056	Molnupiravir for treating COVID-19	Y	No Chapter 5
TA1057	Relugolix–estradiol–norethisterone for treating symptoms of endometriosis	Y	Chapter 6
TA1058	Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)	Terminated appraisal	
HST33	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over	Y	Chapter 8
TA1059	Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma	Y	Chapter 8 incomplete
TA1060	Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer	Y	Chapter 8 incomplete
TA1061	Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)	Terminated appraisal	
TA1062	Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor	Y	Chapter 8 incomplete
TA1063	Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment	Y	Chapter 8 incomplete
TA1064	Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	Y	Chapter 8 incomplete
TA1065	Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	Y	Chapter 8 incomplete
TA1066	Somapacitan for treating growth hormone deficiency in people 3 to 17 years	Y	Chapter 6
TA1067	Linzagolix for treating symptoms of endometriosis	Y	Chapter 6
TA1068	Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)	Terminated appraisal	
TA1069	Efgartigimod for treating antibody-positive generalised myasthenia gravis	Y	Chapter 10
TA1070	Spesolimab for treating generalised pustular psoriasis flares	Y	Chapter 13
TA1071	Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer	Y	Chapter 8 incomplete
TA1072	Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)	Terminated appraisal	
TA1073	Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies	Y	Chapter 2

TA1074	Sparsentan for treating primary IgA nephropathy	Y	Chapter 2
TA1075	Dapagliflozin for treating chronic kidney disease	Y	Chapter 6
TA1076	Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)	Terminated appraisal	
TA1077	Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over	Y	Chapter 13
TA1078	Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)	Terminated appraisal	
TA1079	Fruquintinib for previously treated metastatic colorectal cancer	Y	Chapter 8 incomplete
TA1080	Mirikizumab for previously treated moderately to severely active Crohn's disease	Y	Chapter 1
TA1081	Zanubrutinib for treating relapsed or refractory mantle cell lymphoma	Y	Chapter 8 incomplete
TA1082	Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)	Terminated appraisal	
TA1083	Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)	Terminated appraisal	
TA1084	Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)	Terminated appraisal	
TA1085	Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over	Y	Chapter 3
TA1086	Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence	Y	Chapter 8 incomplete
TA1087	Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen	Y	Chapter 3
TA1088	Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over	Negative recommendation	
TA1089	Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)	Terminated appraisal	
TA1090	Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma	Y	Chapter 8 incomplete
TA1091	Tarlatabam for extensive-stage small-cell lung cancer after 2 or more treatments	Negative recommendation	
TA1092	Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer	Y	Chapter 8 incomplete
TA1093	Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over	Y	Chapter 11
TA1094	Guselkumab for treating moderately to severely active ulcerative colitis	Y	Chapter 1
TA1095	Guselkumab for previously treated moderately to severely active Crohn's disease	Y	Chapter 1
TA1096	Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis	Y	Chapter 3
TA1097	Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable	Y	Chapter 8 incomplete
TA1098	Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable	Y	Chapter 8 incomplete
TA1099	Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy	Y	Chapter 8 incomplete
TA1100	Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)	Terminated appraisal	
TA1101	Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over	Y	Chapter 3
TA1102	Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)	Terminated appraisal	
TA1103	Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor	Y	Chapter 8 incomplete
TA1104	Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)	Terminated appraisal	
TA1105	Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)	Terminated appraisal	

Up-to-date 31/10/25